Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.
Bateman, Lucinda, Bested, Alison C, Bonilla, Hector F et al. · Mayo Clinic proceedings · 2021 · DOI
Quick Summary
This article brings together 21 expert doctors who specialize in ME/CFS to share the best ways to diagnose and treat this complex illness. The experts explain that most people with ME/CFS don't get properly diagnosed, and many receive treatments that can actually make them worse. They provide clear, practical guidance that general doctors can use to help ME/CFS patients feel better and improve their quality of life.
Why It Matters
This guideline is crucial because most ME/CFS patients remain undiagnosed and many receive treatments that worsen their condition, leading to unnecessary suffering and functional decline. With the emergence of post-acute COVID-19 illness that resembles ME/CFS, having clear diagnostic and management guidance helps clinicians help millions more people. This work directly translates recent scientific advances into actionable clinical practice that can meaningfully improve patients' health and quality of life.
Observed Findings
Up to 91% of ME/CFS patients in the United States remain undiagnosed
Graded exercise therapy and cognitive-behavioral therapy have been withdrawn as appropriate treatments by US and other governments and major health organizations
Post-acute COVID-19 illness shares clinical features similar to ME/CFS
A significant percentage of people remain ill for many months following acute COVID-19
The 2015 National Academy of Medicine diagnostic criteria have been adopted by the CDC and represent evidence-based diagnostic standards
Inferred Conclusions
Clinicians require better training and guidance to appropriately diagnose ME/CFS using current evidence-based criteria
Traditional approaches to ME/CFS management have been harmful and should be abandoned in favor of evidence-based practices
Many clinicians can improve patient outcomes through implementation of specialist-recommended management strategies
Post-COVID-19 illness presents a new opportunity to apply ME/CFS diagnostic and management expertise to a larger population
Remaining Questions
Which specific management interventions produce the greatest improvement in functional outcomes and quality of life for different ME/CFS subgroups?
What This Study Does Not Prove
This guideline does not present new experimental data or prove causation of ME/CFS—it synthesizes existing evidence and clinical expertise. It does not establish which specific treatments work best for individual patients, as ME/CFS is heterogeneous and response to interventions varies. The guideline also does not prove that following these recommendations will cure ME/CFS, though it aims to improve management and outcomes.